CA-LANDMARK-WORLDWIDE
17.2.2016 07:02:53 CET | Business Wire | Press release
Landmark Worldwide (www.landmarkworldwide.com ), a global personal and professional growth, training, and development company that delivers programs and courses that empower and develop people to fulfill on what’s really important to them, celebrates its 25th anniversary this month. Known for their leading-edge material and methodology, Landmark’s programs equip people to produce breakthrough results in areas such as career, relationships, productivity, and overall quality of life.
To date, more than 2.4 million people have participated in Landmark programs. Designed for already-effective individuals, The Landmark Forum is the company’s flagship program and runs three days and an evening. Rather than delivering the typical presentation of information and strategies, Landmark’s programs employ a unique, proven, transformational methodology.
“People participate in The Landmark Forum to cause breakthroughs in the areas of their lives that are most important to them,” says CEO Harry Rosenberg. “Our courses are customized to allow individuals to focus on what they really care about. Landmark’s program material and methodology leave people with new ways of seeing themselves, their relationships, and the world around them—people are left with a dramatic elevation in their effectiveness in life, as well as enjoying an extremely high quality of life.”
Of those Landmark Forum participants independently surveyed by IMC Inc., an independent marketing consulting firm, 94 percent agreed that The Landmark Forum made a “profound, lasting difference in the way they live their lives.”
Dr. Joe DiMaggio, Director of Landmark’s Research, Design and Development Division, explains how this is possible: “What makes our methodology and programs unique is that they’re grounded in an ontological and phenomenological model—not in an academic context but from an ‘on-the-court’ applicable perspective. Ontology, in the way we’re using the term, is the study and examination of the nature of what it is to be a human being. By phenomenological we don’t mean something theoretical or conceptual, but rather people examining their lives from how their lives are actually lived. This educational paradigm is distinct from the traditional education that most of us are familiar with, in that its aim is not the delivery of new information that needs to be remembered or applied, but instead to make available unprecedented and lasting breakthroughs in people’s lives that become part of their natural self-expression.”
Landmark’s programs are based on material and methodology created and developed by Werner Erhard (www.wernererhard.com ). Mr. Erhard currently works in academia, writing and lecturing at top universities around the world, most recently on the topics of leadership, integrity, and performance. Renowned Harvard economist Michael C. Jensen, who has collaborated with Erhard on academic articles, papers, and curricula, was recently quoted in The New York Times as stating that Mr. Erhard is “one of the great intellectuals of the century.”
Landmark was formed in 1991 and now offers what many consider to be state-of-the-art programs for impacting people’s performance, effectiveness, and peace of mind. Neuroscience expert Dr. Ken Marton notes that “Landmark’s programs are consistent with the most current neuroscientific studies of human perception and behavior and are truly cutting edge. Their programs for the general public provide a direct access to leadership, individual performance, and enhanced quality of life.”
In addition to using Landmark’s programs to cause breakthroughs on a personal level, many people use them to develop themselves as leaders or to dramatically elevate their effectiveness in providing leadership. For example, more than 100,000 projects have been created out of just one of Landmark's courses, The Self-Expression and Leadership Program. These pro-bono and community projects are designed by participants to make a difference to individuals, communities, and institutions around the world.
Landmark also offers a full range of corporate consulting services internationally through Vanto Group, a wholly owned subsidiary. Clients have ranged from small businesses to Fortune 500 companies and include Apple Inc., Banco do Brasil, BHP Billiton, GlaxoSmithKline (Europe), Guidant Corporation, JPMorgan Chase & Co., Lockheed Martin, Mercedes-Benz USA, NASA, New Zealand Steel, Polus Group (Japan), Reebok International Ltd., Standard Chartered, Tata Group (India), the U.S. Department of Health and Human Services, VisaNet, and Walgreens. Landmark senior program leader and Vanto Group CEO Steve Zaffron co-authored “The Three Laws of Performance: Rewriting the Future of Your Organization and Your Life” (www.threelawsofperformance.com ), which made numerous best-selling lists (including those of Business Week,The Wall Street Journal , and USA Today ) and is now available in 16 languages. Recognized as one of the top leadership and development providers in the world by HR.com/James McNeil, Landmark offers programs that are innovative, effective, and immediately relevant.
Since its founding on February 1, 1991, Landmark has grown to include more than 500 employees and more than 750 extensively trained leaders worldwide. The company is 100 percent owned by its employees through an Employee Stock Ownership Plan (ESOP) and similar international plans.
Landmark has been featured extensively in the press in such media outlets as The New York Times, CNN, The Wall Street Journal, TIME Magazine, Fortune, Fast Company, The Sunday Times (London), The Observer (London), The Sydney Tribune, Bloomberg Businessweek, Investor’s Business Daily, The Huffington Post, The Boston Globe, Chicago Tribune, ABC Nightline, Irish Mail on Sunday , and many more.
For more information, visit Landmark's website (www.landmarkworldwide.com ).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160216006880/en/
Contact:
Landmark Worldwide
Michelle Tennant, 1-828-749-3200
PublicRelations@landmarkworldwide.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
